Above the Genome Editing: The Rise of Epigenome Editing

Today most people have heard about gene editing, but have you heard about epigenome editing? Epigenome editing is a novel way of manipulating gene expression without permanently changing the DNA sequence. The potentially enhanced safety profile and versatility of the epigenome editing platforms have attracted the attention of scientists and investors alike, resulting in the emergence of four new epigenome editing companies, which since 2020 collectively raised $240 million from private and institutional investors. In this report, we highlight eight companies leading the innovation in epigenome editing including Chroma Medicine, Tune Therapeutics, Epic Bio, Sangamo Therapeutics and others and discuss how their platforms will lead to the rise of a new type of epigenetic medicines.